ChemoCentryx Inc (CCXI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH140080D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

October 2018

Total pages

35

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

ChemoCentryx Inc (ChemoCentryx) is a biopharmaceutical company that discovers, develops and commercializes orally-administered therapeutics for the treatment of cancer, autoimmune diseases, and inflammatory disorders. The company's lead drug candidate include Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; CCX872, an orally administered inhibitor for pancreatic cancer; and CCX140, an orally-administered inhibitor of the chemokine receptor known for patients with diabetic nephropathy, among others. It also carries out preclinical research for evaluating the effect of combination therapy with chemokine receptor and check point inhibitors. ChemoCentryx is headquartered in Mountain View, California, the US.

ChemoCentryx Inc (CCXI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

ChemoCentryx Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ChemoCentryx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

ChemoCentryx to Raise USD50 Million in Financing 10

Licensing Agreements 11

Vifor Pharma Enters into Licensing Agreement with ChemoCentryx 11

Vifor Pharma Expands Licensing Agreement with ChemoCentryx for CCX168 12

Equity Offering 13

ChemoCentryx Withdraws Public Offering of Shares for USD75 Million 13

ChemoCentryx Completes Public Offering Of Common Stock For USD 69 Million 15

ChemoCentryx Raises USD7 million in Private Placement of Shares 16

ChemoCentryx Completes IPO Of Common Stock For USD 45 Million 17

ChemoCentryx Completes Private Placement Of Shares For USD 5 Million 19

Acquisition 20

Vifor Pharma to Acquire 14.6% Stake in Chemocentryx from GlaxoSmithKline 20

ChemoCentryx Inc-Key Competitors 22

ChemoCentryx Inc-Key Employees 23

ChemoCentryx Inc-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Financial Announcements 25

Aug 09, 2018: Chemocentryx reports second quarter 2018 financial results and recent highlights 25

May 09, 2018: ChemoCentryx Reports First Quarter 2018 Financial Results and Recent Highlights 27

Mar 09, 2018: ChemoCentryx Reports Fourth Quarter And Full Year 2017 Financial Results And Recent Highlights 28

Nov 07, 2017: ChemoCentryx Reports Third Quarter 2017 Financial Results and Recent Highlights 30

Aug 08, 2017: ChemoCentryx Reports Second Quarter 2017 Financial Results and Recent Highlights 31

May 10, 2017: ChemoCentryx Reports First Quarter 2017 Financial Results 32

Mar 14, 2017: ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results 33

Corporate Communications 34

Jan 08, 2018: ChemoCentryx Strengthens Senior Executive Team with the Appointment of William Fairey as Executive Vice President and Chief Operating Officer 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35


List of Figure

List of Figures

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List of Table

List of Tables

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ChemoCentryx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ChemoCentryx Inc, Deals By Therapy Area, 2012 to YTD 2018 8

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

ChemoCentryx to Raise USD50 Million in Financing 10

Vifor Pharma Enters into Licensing Agreement with ChemoCentryx 11

Vifor Pharma Expands Licensing Agreement with ChemoCentryx for CCX168 12

ChemoCentryx Withdraws Public Offering of Shares for USD75 Million 13

ChemoCentryx Completes Public Offering Of Common Stock For USD 69 Million 15

ChemoCentryx Raises USD7 million in Private Placement of Shares 16

ChemoCentryx Completes IPO Of Common Stock For USD 45 Million 17

ChemoCentryx Completes Private Placement Of Shares For USD 5 Million 19

Vifor Pharma to Acquire 14.6% Stake in Chemocentryx from GlaxoSmithKline 20

ChemoCentryx Inc, Key Competitors 22

ChemoCentryx Inc, Key Employees 23

ChemoCentryx Inc, Subsidiaries 24

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022